Inflammation and Benign Prostatic Hyperplasia

Urologic Clinics of North America

Volumn 35, Issue 1, 2008, Pages 109-115

  Nickel, J Curtis ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; IBUPROFEN; MALONALDEHYDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AREA UNDER THE CURVE; BACTERIUM CULTURE; CANCER RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EJACULATION; HISTOLOGY; HUMAN; MONOTHERAPY; PATHOGENESIS; PHYTOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; REVIEW;

BIOLOGICAL MARKERS; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATITIS;

EID: 36448975493     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.09.012     Document Type: Review

References (46)

1. Berry S.J., Coffey D.S., Walsh P.C., et al. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984) 474-479
2. Krieger J.N., Nyberg L., and Nickel J.C. NIH consensus definition and classification of prostatitis. JAMA 282 (1999) 236-237
3. Schaeffer A.J., Knauss J.S., Landis J.R., et al. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the NIH chronic prostatitis cohort (CPC) study. J Urol 168 3 (2002) 1048-1053
4. Nickel J.C., Alexander R.B., Schaeffer A.J., et al. Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. J Urol 170 3 (2003) 818-822
5. True L.D., Berger R.E., Rothman I., et al. Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. J Urol 162 (1999) 2014-2018
6. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 (2004) 1314-1317
7. Nickel J.C., Roehrborn C.G., O'Leary M.P., et al. Examination of the relationship between symptoms of prostatitis and histologic inflammation: baseline data from the REDUCE chemoprevention trial. J Urol 178 (2007) 896-901
8. Pontari M.A. Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment. Drugs Aging 20 (2003) 1111-1125
9. Roberts R.O., Lieber M.M., Rhodes T., et al. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 51 (1998) 578-584
10. Nickel J.C., Downey J., Hunter D., et al. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health Chronic Prostatitis Symptom Index. J Urol 165 (2001) 842-845
11. Collins M.M., Stafford R.S., O'Leary M.P., et al. Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits. Urology 53 (1999) 921-925
12. Collins M.M., Meigs J.B., Barry M.J., et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 167 3 (2002) 1363-1366
13. Shoskes D.A., Landis J.R., Wang Y., et al. Impact of post-ejaculatory pain in men with category III chronic prostatitis/chronic pelvic pain syndrome. J Urol 172 (2004) 542-547
14. Vallancien G., Emberton M., Harving N., et al. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 169 6 (2003) 2257-2261
15. Frankel S.J., Donovan J.L., Peters T.J., et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 51 8 (1998) 677-685
16. Brookes S.J., Donovan J.L., Peters T.J., et al. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomized control trial. Br Med J 324 (2002) 1059-1061
17. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44 (2003) 637-649
18. Nickel J.C., Elhilali M., Vallancien G., and for the ALF-ONE Study Group. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int 95 (2005) 571-574
19. St. Sauver J.L., Jacobson D.J., McGree M.E., et al. Association between prostatitis and development of benign prostatic hyperplasia. J Urol 177 Suppl 4 (2007) 497 (abstract 1506)
20. Kohnen P.W., and Drach G.W. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 121 (1979) 755-760
21. Nickel J.C. Prostatic inflammation in benign prostatic hyperplasia-the third component?. Can J Urol 1 1 (1994) 1-4
22. Odunjo E.O., and Elebute E.A. Chronic prostatitis in benign prostatic hyperplasia. Br J Urol 43 (1971) 333-337
23. Nickel J.C., Downey J., Young I., et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 84 (1999) 976-981
24. Nickel J.C., True L.D., Kreiger J.N., et al. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 87 (2001) 797-805
25. Nickel J.C., Roehrborn C.G., O'Leary M.P., et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. J Urol 177 Suppl 4 (2007) 34-35 (abstract 98)
26. Minnery C.H., and Getzenberg R.H. Benign prostatic hyperplasia cell line viability and modulation of JM-27 by Doxazosin and Ibuprofen. J Urol 174 (2005) 375-379
27. Di Silverio F., Bosman C., Slavatori M., et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 47 (2005) 72-79
28. Buck A.C. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172 (2004) 1792-1799
29. Lee K.L., and Peehl D.M. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 172 (2004) 1784-1791
30. Untergasser G., Madersbacher S., and Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 40 (2005) 121-128
31. Kramer G., and Marberger M. Could inflammation be a key component in the progession of benign prostatic hyperplasia?. Curr Opin Urol 16 (2006) 25-29
32. Theyer G., Kramer G., and Assmann I. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 66 (1992) 96-107
33. Steiner G., Gessl A., Kramer G., et al. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 151 (1994) 480-484
34. Kramer G., Steiner G.E., Handisurya A., et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 52 (2002) 43-48
35. Handisurya A., Steiner G.E., Stix U., et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate 49 (2001) 251-262
36. Steiner G., Stix U., Handisurya A., et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 83 (2003) 1131-1146
37. Konig J.E., Senge T., Allhoff E.P., et al. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 58 (2004) 121-129
38. Wang W., Bergh A., and Damber J.E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61 (2004) 60-72
39. Kakehi Y., Segawa T., Wu X.X., et al. Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. Prostate 59 (2004) 351-356
40. Vykhovanets E.V., Resnick M.I., and Marengo S.R. The healthy rat prostate contains high levels of natural killer-like cells and unique subsets of CD4+ helperinducer T cells: implications for prostatitis. J Urol 173 (2005) 1004-1010
41. Kramer G., Mitteregger D., and Marberger M. Is benign prostatic hyperplasia (bph) an immune inflammatory disease?. Eur Urol 51 (2007) 1202-1216
42. Roehrborn C.G. Definition of at-risk patients: baseline variables. BJU Int 97 Suppl 2 (2006) 7-11
43. Merendino R.A., Salvo F., Saija A., et al. Malondialdehyde in benign prostatic hypertrophy: a useful marker?. Mediators Inflamm 12 (2003) 127-128
44. Rohrmann S., De Marzo A.M., Smit E., et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the third national health and nutrition examination survey (NHANES III). Prostate 52 (2005) 43-58
45. Castro P., Xia C., Gomez L., et al. Interleukin-8 exression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 60 (2005) 153-159
46. Penna G., Mondaini N., Amuchastegui S., et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin-8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 51 (2007) 524-533